Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer-Reference-Cited by-同舟云学术

Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer

Published:2019-11-13 Issue:1 Volume:9 Page:151-159
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Wang De‐shen¹^ORCID,Wang Zhi‐qiang¹,Chen Gong²,Peng Jie‐wen³,Wang Wei⁴,Deng Yan‐hong⁵^ORCID,Wang Feng‐hua¹^ORCID,Zhang Jian‐wei⁵,Liang Han‐lin³,Feng Fen⁴,Xie Chuan‐bo⁶,Ren Chao¹,Jin Ying¹,Shi Si‐mei¹,Fan Wen‐hua²,Lu Zhen‐hai²,Ding Pei‐rong²,Wang Feng¹,Xu Rui‐hua¹^ORCID,Li Yu‐hong¹^ORCID

Affiliation:

1. State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Department of Medical Oncology Sun Yat‐sen University Cancer Center Guangzhou China

2. State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Department of Colorectal Surgery Sun Yat‐sen University Cancer Center Guangzhou China

3. Zhongshan People's Hospital Zhongshan China

4. The First People's Hospital of Foshan City Foshan China

5. The Sixth Affiliated Hospital of Sun Yat‐sen University Guangzhou China

6. State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Department of Cancer Prevention Research Sun Yat‐sen University Cancer Center Guangzhou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2693

Reference32 articles.

1. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

2. Therapy for Metastatic Colorectal Cancer

3. Central and peripheral nervous system toxicity of common chemotherapeutic agents